Kagocel 12 mg 20 tablets

The drug Kagocel is used in adults and children aged 3 years and older as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

Orally, regardless of food intake.
For the treatment of influenza and ARVI in adults, the recommended dosage is 2 tablets 3 times a day for the first two days, followed by 1 tablet 3 times a day for the next two days. Total course: 18 tablets; duration of the course: 4 days.
For the prevention of influenza and ARVI in adults, 7-day cycles are recommended: for two days, take 2 tablets once a day, followed by a 5-day break, then repeat the cycle. Duration of the preventive course: from one week to several months.
For the treatment of herpes in adults, the dosage is 2 tablets 3 times a day for 5 days. Total course: 30 tablets; duration of the course: 5 days.
For the treatment of influenza and ARVI in children aged 3 to 6 years, the recommended dosage is 1 tablet 2 times a day for the first two days, followed by 1 tablet once a day for the next two days. Total course: 6 tablets; duration of the course: 4 days.
For the treatment of influenza and ARVI in children aged 6 years and older, the recommended dosage is 1 tablet 3 times a day for the first two days, followed by 1 tablet 2 times a day for the next two days. Total course: 10 tablets; duration of the course: 4 days.
For the prevention of influenza and ARVI in children aged 3 years and older, 7-day cycles are recommended: for two days, take 1 tablet once a day, followed by a 5-day break, then repeat the cycle. Duration of the preventive course: from one week to several months.
If there is no improvement after treatment, or if symptoms worsen, or if new symptoms appear, consult a doctor.
Use the medication only according to the indications, method of use, and dosages specified in the instructions.

Composition per 1 tablet:
Active ingredient: Kagocel (calculated as dry substance) - 12 mg.
Excipients: Potato starch - 10 mg; Calcium stearate - 0.65 mg; Ludipress (composition: Lactose monohydrate - from 91% to 95%, Povidone (Kollidon 30) - from 3.0% to 4.0%, Crospovidone (Kollidon CL) - from 3.0% to 4.0%) - to obtain a tablet mass of 100 mg.

Tablets from white with a brownish tint to light brown color, round, biconvex with brown speckles.

• Pregnancy and breastfeeding;

• Age under 3 years;

• Increased sensitivity to the components of the product;

• Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
With caution:
Pregnancy and lactation:
Due to the lack of necessary clinical data, the product is contraindicated during pregnancy and breastfeeding.

To achieve a therapeutic effect, the medication should be started no later than the fourth day from the onset of the disease.
Effect on the ability to drive vehicles and operate machinery:
The effect of the medication on the ability to drive vehicles and operate machinery has not been studied.

Allergic reactions may occur.
If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, inform your doctor.

In case of accidental overdose, it is recommended to administer plenty of fluids and induce vomiting.

The drug Kagocel works well in combination with other antiviral medications, immunomodulators, and antibiotics (additive effect).

The main mechanism of action of Kagocel is its ability to induce the production of interferons. Kagocel stimulates the formation of so-called late interferons in the human body, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel induces the production of interferons in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. After oral administration of a single dose of Kagocel, the interferon titer in the blood serum reaches its maximum values after 48 hours. The interferon response of the body to the administration of Kagocel is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine after oral administration of Kagocel does not coincide with the dynamics of circulating interferon titers. In the blood serum, the production of interferons reaches high values only 48 hours after taking Kagocel, while in the intestine, the peak production of interferons is observed as early as 4 hours after administration.

Kagocel, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic, and does not exhibit embryotoxic effects.

The greatest effectiveness in the treatment with Kagocel is achieved when it is administered no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the infectious agent.

After 24 hours of administration, Kagocel accumulates primarily in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are noted in adipose tissue, heart, muscles, testes, brain, and blood plasma. The low content of Kagocel in the brain is explained by the high molecular weight of the drug, which hinders its penetration through the blood-brain barrier. In blood plasma, the drug is predominantly in a bound form.

With daily multiple administrations of Kagocel, the volume of distribution varies widely across all studied organs. The accumulation of the drug is particularly pronounced in the spleen and lymph nodes. When taken orally, approximately 20% of the administered dose enters the systemic circulation. The absorbed drug circulates in the blood mainly in a form bound to macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug constitutes about 16%.

Excretion: the drug is primarily eliminated from the body through the intestines: 88% of the administered dose is excreted within 7 days, including 90% through the intestines and 10% through the kidneys. The drug is not detected in exhaled air.

Kagocel is a modern medication with immunostimulatory properties. It helps strengthen the body's defense mechanisms and aids in combating viral infections. Kagocel is effective both as a preventive measure and for the treatment of influenza, colds, and other infectious diseases. The medication is taken according to a specific regimen. Kagocel is a safe and well-tolerated drug, it does not cause side effects and does not interact with other medications. The package contains 20 tablets of 12 mg each.